Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 25 | 2020 | 192 | 7.940 |
Why?
|
| Thyroidectomy | 18 | 2024 | 101 | 4.790 |
Why?
|
| Parathyroidectomy | 16 | 2023 | 49 | 3.730 |
Why?
|
| Carcinoma, Papillary | 9 | 2017 | 76 | 2.590 |
Why?
|
| Natural Orifice Endoscopic Surgery | 5 | 2024 | 69 | 2.160 |
Why?
|
| Parathyroid Hormone | 8 | 2019 | 72 | 1.850 |
Why?
|
| Thyroid Gland | 7 | 2023 | 117 | 1.780 |
Why?
|
| Endocrine Surgical Procedures | 3 | 2021 | 5 | 1.550 |
Why?
|
| Hyperparathyroidism, Primary | 9 | 2023 | 33 | 1.520 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 3 | 2021 | 16 | 1.470 |
Why?
|
| Parathyroid Neoplasms | 6 | 2016 | 22 | 1.360 |
Why?
|
| Hypocalcemia | 4 | 2018 | 35 | 1.350 |
Why?
|
| Hyperparathyroidism, Secondary | 3 | 2018 | 14 | 1.300 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2016 | 65 | 1.290 |
Why?
|
| Carcinoma | 4 | 2016 | 282 | 1.270 |
Why?
|
| Thyroid Nodule | 3 | 2018 | 20 | 1.260 |
Why?
|
| Adrenalectomy | 4 | 2019 | 35 | 1.220 |
Why?
|
| Parathyroid Glands | 5 | 2023 | 29 | 1.200 |
Why?
|
| Quality of Life | 7 | 2024 | 1905 | 1.120 |
Why?
|
| Adenoma | 5 | 2015 | 134 | 1.100 |
Why?
|
| Adenocarcinoma, Follicular | 5 | 2017 | 11 | 1.000 |
Why?
|
| Robotic Surgical Procedures | 3 | 2019 | 198 | 0.980 |
Why?
|
| Survivors | 3 | 2016 | 345 | 0.970 |
Why?
|
| Calcium | 6 | 2016 | 1096 | 0.940 |
Why?
|
| Pathologists | 1 | 2022 | 29 | 0.830 |
Why?
|
| Hyperaldosteronism | 2 | 2019 | 15 | 0.800 |
Why?
|
| Hypoparathyroidism | 1 | 2021 | 11 | 0.790 |
Why?
|
| Postoperative Complications | 6 | 2018 | 2998 | 0.780 |
Why?
|
| Middle Aged | 34 | 2024 | 25588 | 0.740 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 689 | 0.710 |
Why?
|
| Physicians | 2 | 2018 | 582 | 0.670 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 37 | 0.650 |
Why?
|
| Male | 44 | 2024 | 59581 | 0.650 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 710 | 0.640 |
Why?
|
| Calcium Gluconate | 1 | 2018 | 6 | 0.640 |
Why?
|
| Medical History Taking | 1 | 2019 | 106 | 0.630 |
Why?
|
| Calcitriol | 1 | 2018 | 82 | 0.620 |
Why?
|
| Female | 45 | 2024 | 64939 | 0.620 |
Why?
|
| Cancer Survivors | 2 | 2018 | 187 | 0.600 |
Why?
|
| Adult | 29 | 2024 | 28743 | 0.600 |
Why?
|
| Social Perception | 1 | 2018 | 57 | 0.580 |
Why?
|
| Aged | 22 | 2023 | 18779 | 0.570 |
Why?
|
| Humans | 57 | 2024 | 122412 | 0.570 |
Why?
|
| Preoperative Care | 2 | 2018 | 350 | 0.550 |
Why?
|
| Ultrasonic Surgical Procedures | 1 | 2016 | 2 | 0.550 |
Why?
|
| Postoperative Care | 1 | 2018 | 291 | 0.540 |
Why?
|
| Electrosurgery | 1 | 2016 | 19 | 0.540 |
Why?
|
| SEER Program | 5 | 2016 | 193 | 0.530 |
Why?
|
| Travel | 1 | 2017 | 117 | 0.530 |
Why?
|
| Gastric Bypass | 1 | 2016 | 68 | 0.510 |
Why?
|
| Spirituality | 1 | 2015 | 47 | 0.500 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2018 | 111 | 0.500 |
Why?
|
| Disease Management | 1 | 2019 | 513 | 0.500 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 155 | 0.500 |
Why?
|
| Epigenomics | 1 | 2016 | 163 | 0.490 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 174 | 0.480 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 398 | 0.480 |
Why?
|
| Rare Diseases | 2 | 2016 | 185 | 0.480 |
Why?
|
| Medical Errors | 1 | 2016 | 155 | 0.470 |
Why?
|
| Incidence | 8 | 2016 | 3008 | 0.470 |
Why?
|
| Incidental Findings | 3 | 2015 | 124 | 0.470 |
Why?
|
| Pheochromocytoma | 2 | 2011 | 33 | 0.460 |
Why?
|
| Social Behavior | 1 | 2015 | 206 | 0.460 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 180 | 0.460 |
Why?
|
| Biological Assay | 1 | 2014 | 101 | 0.460 |
Why?
|
| Neck Dissection | 3 | 2019 | 18 | 0.450 |
Why?
|
| Health Status | 1 | 2015 | 366 | 0.440 |
Why?
|
| Hypertension | 2 | 2019 | 1265 | 0.430 |
Why?
|
| Laparoscopy | 2 | 2018 | 503 | 0.430 |
Why?
|
| Mass Screening | 1 | 2018 | 779 | 0.420 |
Why?
|
| Chicago | 3 | 2016 | 20 | 0.370 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 927 | 0.340 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1009 | 0.340 |
Why?
|
| Prognosis | 8 | 2023 | 4492 | 0.340 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 4984 | 0.330 |
Why?
|
| Case-Control Studies | 4 | 2019 | 3231 | 0.330 |
Why?
|
| DNA Methylation | 1 | 2016 | 991 | 0.330 |
Why?
|
| Survival Rate | 6 | 2016 | 2001 | 0.330 |
Why?
|
| Liver | 1 | 2016 | 1858 | 0.320 |
Why?
|
| Cohort Studies | 7 | 2018 | 4648 | 0.320 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 1227 | 0.320 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1633 | 0.310 |
Why?
|
| Age Factors | 5 | 2016 | 2779 | 0.310 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1431 | 0.310 |
Why?
|
| Retrospective Studies | 16 | 2018 | 15879 | 0.300 |
Why?
|
| Clinical Competence | 1 | 2014 | 970 | 0.290 |
Why?
|
| Sex Factors | 3 | 2015 | 1234 | 0.260 |
Why?
|
| Technetium Tc 99m Sestamibi | 3 | 2014 | 25 | 0.240 |
Why?
|
| United States | 7 | 2019 | 10475 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1247 | 0.240 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2480 | 0.220 |
Why?
|
| Terminology as Topic | 2 | 2015 | 226 | 0.220 |
Why?
|
| Risk Factors | 6 | 2016 | 9868 | 0.200 |
Why?
|
| Nephrolithiasis | 2 | 2011 | 14 | 0.200 |
Why?
|
| Endoscopy | 2 | 2021 | 283 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 6303 | 0.190 |
Why?
|
| Prospective Studies | 4 | 2024 | 5970 | 0.190 |
Why?
|
| False Negative Reactions | 2 | 2018 | 89 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2016 | 1119 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1005 | 0.180 |
Why?
|
| Time Factors | 3 | 2016 | 6176 | 0.180 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 222 | 0.180 |
Why?
|
| Ultrasonography | 5 | 2017 | 945 | 0.170 |
Why?
|
| Cicatrix | 1 | 2021 | 125 | 0.170 |
Why?
|
| Lymph Node Excision | 2 | 2017 | 157 | 0.170 |
Why?
|
| Clinical Chemistry Tests | 1 | 2019 | 5 | 0.160 |
Why?
|
| Radiopharmaceuticals | 3 | 2014 | 158 | 0.160 |
Why?
|
| Publication Bias | 1 | 2018 | 11 | 0.160 |
Why?
|
| Hypokalemia | 1 | 2018 | 41 | 0.160 |
Why?
|
| Immunoassay | 1 | 2019 | 127 | 0.150 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 2813 | 0.150 |
Why?
|
| Young Adult | 7 | 2016 | 8805 | 0.150 |
Why?
|
| Risk Adjustment | 1 | 2018 | 58 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 539 | 0.140 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 3611 | 0.140 |
Why?
|
| Hematoma | 1 | 2018 | 93 | 0.140 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2016 | 81 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 391 | 0.130 |
Why?
|
| Body Temperature | 1 | 2016 | 103 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2018 | 376 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2019 | 12035 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 2077 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 76 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 297 | 0.130 |
Why?
|
| Adolescent | 6 | 2016 | 18971 | 0.120 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 195 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 695 | 0.120 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2014 | 4 | 0.120 |
Why?
|
| Frozen Sections | 1 | 2014 | 24 | 0.120 |
Why?
|
| Canada | 1 | 2015 | 294 | 0.120 |
Why?
|
| Hyperostosis Frontalis Interna | 1 | 2014 | 3 | 0.120 |
Why?
|
| Finland | 1 | 2014 | 42 | 0.120 |
Why?
|
| Hospitals | 1 | 2018 | 397 | 0.120 |
Why?
|
| CpG Islands | 1 | 2016 | 321 | 0.120 |
Why?
|
| Educational Status | 1 | 2015 | 267 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2018 | 516 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 473 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 423 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 236 | 0.110 |
Why?
|
| Age of Onset | 1 | 2015 | 580 | 0.110 |
Why?
|
| Monitoring, Intraoperative | 1 | 2014 | 130 | 0.110 |
Why?
|
| Linear Models | 1 | 2015 | 655 | 0.110 |
Why?
|
| Psychometrics | 1 | 2017 | 660 | 0.110 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2013 | 9 | 0.110 |
Why?
|
| Communication | 1 | 2018 | 504 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2019 | 1300 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 285 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 394 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 3305 | 0.110 |
Why?
|
| Length of Stay | 1 | 2018 | 1272 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2014 | 750 | 0.110 |
Why?
|
| ROC Curve | 1 | 2014 | 552 | 0.100 |
Why?
|
| Swine | 1 | 2016 | 1159 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 635 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2019 | 994 | 0.100 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 160 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2014 | 995 | 0.100 |
Why?
|
| Comorbidity | 1 | 2017 | 1488 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1403 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 586 | 0.100 |
Why?
|
| Hypercalciuria | 1 | 2011 | 7 | 0.100 |
Why?
|
| Logistic Models | 1 | 2016 | 1767 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2013 | 239 | 0.100 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2011 | 12 | 0.090 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2010 | 5 | 0.090 |
Why?
|
| Azacitidine | 1 | 2010 | 55 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2016 | 1412 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1714 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 75 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 2035 | 0.090 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2010 | 17 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 714 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2016 | 3306 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2013 | 361 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 178 | 0.080 |
Why?
|
| Prevalence | 1 | 2015 | 2369 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 354 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2011 | 233 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 315 | 0.080 |
Why?
|
| Registries | 1 | 2014 | 1378 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2582 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 862 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2012 | 621 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 608 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1874 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2017 | 378 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3456 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2015 | 194 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2014 | 151 | 0.050 |
Why?
|
| Israel | 1 | 2021 | 44 | 0.050 |
Why?
|
| Public Opinion | 1 | 2021 | 56 | 0.050 |
Why?
|
| Mouth | 1 | 2021 | 56 | 0.050 |
Why?
|
| Operative Time | 1 | 2021 | 158 | 0.040 |
Why?
|
| Child | 3 | 2015 | 24108 | 0.040 |
Why?
|
| Recurrence | 2 | 2014 | 1412 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 73 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 197 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 170 | 0.040 |
Why?
|
| Video-Assisted Surgery | 1 | 2015 | 5 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 231 | 0.030 |
Why?
|
| Animals | 1 | 2016 | 33898 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 267 | 0.030 |
Why?
|
| Thymectomy | 1 | 2014 | 24 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 871 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 607 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 673 | 0.030 |
Why?
|
| Kidney Calculi | 1 | 2012 | 40 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2012 | 82 | 0.020 |
Why?
|
| Calcium Oxalate | 1 | 2011 | 24 | 0.020 |
Why?
|
| Global Health | 1 | 2016 | 556 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 218 | 0.020 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2010 | 18 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 56 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 96 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 94 | 0.020 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2010 | 42 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 138 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2012 | 308 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2010 | 165 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2012 | 0.020 |
Why?
|
| Shock, Cardiogenic | 1 | 2010 | 189 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2014 | 842 | 0.020 |
Why?
|
| Depression | 1 | 2012 | 1204 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 3302 | 0.010 |
Why?
|
| Neoplasms | 1 | 2016 | 2752 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 12347 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2011 | 13837 | 0.010 |
Why?
|